Literature DB >> 3426918

The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow.

J W Croese1, C M Vas Nunes, J Radl, M H van den Enden-Vieveen, R J Brondijk, W J Boersma.   

Abstract

The transplantable C57BL/KaLwRij mouse 5T2 multiple myeloma (MM) is a new animal model for studies on MM in man. Histological examination of the 5T2 MM cells revealed their morphological heterogeneity. In this study we investigated whether this heterogeneity reflects subpopulations of 5T2 MM cells with different biological properties. 5T2 MM bone marrow cells were separated according to their sedimentation velocity (s.v.). When intravenously injected into syngeneic recipient mice, cells with s.v. of 8 mm h-1 led to the development of detectable 5T2 MM after 6 weeks; in contrast, 18 weeks elapsed before the same result was achieved with cells of s.v. lower than 5 mm h-1. Flow cytometric analysis revealed that 5T2 MM cells had an aneuploid DNA content and that most cycling 5T2 MM cells were large, their s.v. rate exceeding 9 mm h-1. It was further demonstrated that about half of all aneuploid cells carried on their membrane the 5T2 MM idiotype. The majority of the idiotype-positive cells had s.v. rate exceeding 6.5 mm h-1 (16%-39%) or lower than 3 mm h-1 (16%-19%). The 5T2 MM was shown to contain subpopulations of cells of different size, proliferation capacity and expression of their membrane 5T2 idiotype; this, most likely reflects cells in different stages of differentiation. The mouse 5T2 MM corresponds also in this respect with MM in man.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3426918      PMCID: PMC2001900          DOI: 10.1038/bjc.1987.241

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Myeloma cell immunoglobulin expression during in vivo growth in diffusion chambers: evidence for repetitive cycles of differentiation.

Authors:  J W Rohrer; K Vasa; R G Lynch
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

2.  An immunofluorescence procedure for the detection of intracellular immunoglobulins.

Authors:  W Hijmans; H R Schuit; F Klein
Journal:  Clin Exp Immunol       Date:  1969-04       Impact factor: 4.330

3.  A rapid single step staining technique for DNA analysis by flow microfluorimetry.

Authors:  I W Taylor
Journal:  J Histochem Cytochem       Date:  1980-09       Impact factor: 2.479

Review 4.  Multiple myeloma, Waldenström's macroglobulinemia, and benign monoclonal gammopathy: characteristics of the B cell clone, immunoregulatory cell populations and clinical implications.

Authors:  H Mellstedt; G Holm; M Björkholm
Journal:  Adv Cancer Res       Date:  1984       Impact factor: 6.242

5.  Cellular DNA content as a marker of human multiple myeloma.

Authors:  J Latreille; B Barlogie; G Dosik; D A Johnston; B Drewinko; R Alexanian
Journal:  Blood       Date:  1980-03       Impact factor: 22.113

6.  Age-related changes in the relative numbers of Thy-1- and Lyt-2-bearing peripheral blood lymphocytes in mice: a longitudinal approach.

Authors:  W J Boersma; F A Steinmeier; J J Haaijman
Journal:  Cell Immunol       Date:  1985-07       Impact factor: 4.868

7.  Light scattering properties of murine hemopoietic cells.

Authors:  J W Visser; G J van den Engh; D W van Bekkum
Journal:  Blood Cells       Date:  1980

8.  Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.

Authors:  F Caligaris-Cappio; L Bergui; L Tesio; G Pizzolo; F Malavasi; M Chilosi; D Campana; B van Camp; G Janossy
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

9.  Cytogenetic evidence that the malignant event in multiple myeloma occurs in a precursor lymphocyte.

Authors:  M R MacKenzie; J P Lewis
Journal:  Cancer Genet Cytogenet       Date:  1985-05

10.  Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma.

Authors:  J Radl; J W Croese; C Zurcher; M H van den Enden-Vieveen; R J Brondijk; M Kazil; J J Haaijman; P H Reitsma; O L Bijvoet
Journal:  Cancer       Date:  1985-03-01       Impact factor: 6.860

View more
  10 in total

1.  Animal model of human disease. Multiple myeloma.

Authors:  J Radl; J W Croese; C Zurcher; M H Van den Enden-Vieveen; A M de Leeuw
Journal:  Am J Pathol       Date:  1988-09       Impact factor: 4.307

2.  Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model.

Authors:  W Grady Gunn; Ulf Krause; Narae Lee; Carl A Gregory
Journal:  Blood       Date:  2010-12-01       Impact factor: 22.113

Review 3.  Animal Models of Bone Metastasis.

Authors:  J K Simmons; B E Hildreth; W Supsavhad; S M Elshafae; B B Hassan; W P Dirksen; R E Toribio; T J Rosol
Journal:  Vet Pathol       Date:  2015-05-28       Impact factor: 2.221

4.  An in vivo model of human multidrug-resistant multiple myeloma in SCID mice.

Authors:  W T Bellamy; A Odeleye; P Finley; B Huizenga; W S Dalton; R S Weinstein; E M Hersh; T M Grogan
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

5.  Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4.

Authors:  Leonardo Mirandola; Yuefei Yu; Marjorie R Jenkins; Raffaella Chiaramonte; Everardo Cobos; Constance M John; Maurizio Chiriva-Internati
Journal:  BMC Cancer       Date:  2011-09-16       Impact factor: 4.430

6.  The 5T mouse multiple myeloma model: absence of c-myc oncogene rearrangement in early transplant generations.

Authors:  J Radl; Y A Punt; M H van den Enden-Vieveen; P A Bentvelzen; M H Bakkus; T W van den Akker; R Benner
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

7.  GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice.

Authors:  Natasha Friend; Jacqueline E Noll; Khatora S Opperman; Kimberley C Clark; Krzysztof M Mrozik; Kate Vandyke; Duncan R Hewett; Andrew C W Zannettino
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

Review 8.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

9.  A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse.

Authors:  L S Manning; J D Berger; H L O'Donoghue; G N Sheridan; P G Claringbold; J H Turner
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

Review 10.  Immunological dysregulation in multiple myeloma microenvironment.

Authors:  Alessandra Romano; Concetta Conticello; Maide Cavalli; Calogero Vetro; Alessia La Fauci; Nunziatina Laura Parrinello; Francesco Di Raimondo
Journal:  Biomed Res Int       Date:  2014-06-11       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.